Migraine therapy during pregnancy and lactation

Bibliography

• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
   PubMed Web of Science ®Google Scholar
• The National Headache Foundation. Available from: www.headache.org/
   Google Scholar
• Olesen J, Goadsby PJ, Ramadan NM, The Headaches. 3rd edition. Williams & Wilkins, Philadelphia, Lippincott; 2006
   Google Scholar
• Brandes JL. Headache related to pregnancy: management of migraine and migraine headache in pregnancy. Curr Treat Options Neurol 2008;10:12-9
   PubMed Web of Science ®Google Scholar
• Melhado EM, Maciel JA Jr, Guerreiro CAM. Headache during gestation: Evaluation of 1101 women. Can J Neurol Sci 2007;34:187-92
   PubMed Web of Science ®Google Scholar
• Sances G, Granella F, Nappi RE, Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003;23:197-205
   PubMed Web of Science ®Google Scholar
• Maggioni F, Alessi C, Maggino T, Headache during pregnancy. Cephalalgia 1997;17:765-9
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Zanferrari C, Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-9
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine and pregnancy. Neurol Clin 1997;15:209-31
   PubMed Web of Science ®Google Scholar
• Wainscott G, Sullivan FM, Volans GN, The outcome of pregnancy in women suffering from migraine. Postgrad Med J 1978;54:98-102
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Pucci E, Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000;20:701-7
   PubMed Web of Science ®Google Scholar
• Banhidy F, Acs N, Horvath-Puho E, Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur J Obstet Gynecol Reprod Biol 2007;134:157-63
   PubMed Web of Science ®Google Scholar
• Chen HM, Chen SF, Chen YH, Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia 2009;30:433-8
   Web of Science ®Google Scholar
• Nezvalova-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia 2009;29:1267-76
   PubMed Web of Science ®Google Scholar
• Schardein JL. Chemically induced birth defects. 2nd edition. Marcel Deker, New York; 1993
   Google Scholar
• Pesaturo KA, Wooding FG. Modern management of the migraine headache. Am J Lifestyle Med 2009;3:147-59
   Google Scholar
• Linde K, Allais G, Brinkhaus B, Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009;(1):CD007587
   Google Scholar
• Evers S, Afra J, Frese A, EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
   PubMed Web of Science ®Google Scholar
• Killick S, Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987;47:773-7
   PubMed Web of Science ®Google Scholar
• Nielsen GL, Sorensen HT, Larsen H, Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-70
   PubMed Web of Science ®Google Scholar
• Li DK, Liu LY, Douh R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J 2003;327:368-71
   PubMed Web of Science ®Google Scholar
• Nielsen GL, Skriver MV, Pedersen L, Danish group reanalyses miscarriage in NSAID users. Br Med J 2004;328:109
   PubMed Web of Science ®Google Scholar
• Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7
   PubMedGoogle Scholar
• Torfs CP, Katz EA, Bateson TF, Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92
   PubMedGoogle Scholar
• Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997;56:241-3
   PubMedGoogle Scholar
• Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31
   PubMed Web of Science ®Google Scholar
• Kozer E, Nikfar S, Costei A, Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Obstet Gynecol 2002;187:1623-30
   Web of Science ®Google Scholar
• Ericson A, Kallen BAJ. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5
   PubMed Web of Science ®Google Scholar
• Ofori B, Oraichi D, Blais L, Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79
   PubMed Web of Science ®Google Scholar
• Momma K, Hagiwara H, Konishi T. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs:study of additional 34 drugs. Prostaglandins 1984;28:527-36
   PubMed Web of Science ®Google Scholar
• Norton ME, Merrill J, Cooper B, Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-7
   PubMed Web of Science ®Google Scholar
• Vermillion ST, Scardo JA, Lashus AG, The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Obstet Gynecol 1997;177:256-9
   Web of Science ®Google Scholar
• Vandenveyver IB, Moise KJ, Ou CN, The effect of gestational-age and fetal indomethacin levels on the incidence of constriction of the fetal ductus-arteriosus. Obstet Gynecol 1993;82:500-3
   PubMed Web of Science ®Google Scholar
• Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology 1997;56:282-92
   PubMedGoogle Scholar
• Levin DL, Fixler DE, Morriss FC, Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 1978;92:478-83
   PubMed Web of Science ®Google Scholar
• Moise KJ Jr, Huhta JC, Sharif DS, Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988;319:327-31
   PubMed Web of Science ®Google Scholar
• Alano MA, Ngougmna E, Ostrea EM, Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23
   PubMed Web of Science ®Google Scholar
• Zenker M, Klinge J, Kruger C, Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998;26:231-4
   PubMed Web of Science ®Google Scholar
• Mas C, Menahem S. Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. Aust NZ J Obstet Gynaecol 1999;39:106-7
   PubMed Web of Science ®Google Scholar
• Rein AJ, Nadjari M, Elchalal U, Contraction of the fetal ductus arteriosus induced by diclofenac – case report. Fetal Diagn Ther 1999;14:24-5
   PubMed Web of Science ®Google Scholar
• Corby DG. Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978;62:930-7
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110(Suppl 3A):20S-7S
   PubMedGoogle Scholar
• Hickok DE, Hollenbach KA, Reilley SF, The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989;160:1525-30; discussion 1530-1
   PubMed Web of Science ®Google Scholar
• van der Heijden B, Gubler MC. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1995;9:675
   PubMed Web of Science ®Google Scholar
• Rumack CM, Guggenheim MA, Rumack BH, Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981;58:52S-6S
   Web of Science ®Google Scholar
• Baerts W, Fetter WP, Hop WC, Cerebral lesions in preterm infants after tocolytic indomethacin. Dev Med Child Neurol 1990;32:910-8
   PubMed Web of Science ®Google Scholar
• Doyle NM, Gardner MO, Wells L, Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. J Perinatol 2005;25:336-40
   PubMedGoogle Scholar
• [Anon]CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994;343:619-29
   PubMed Web of Science ®Google Scholar
• Di Sessa TG, Moretti ML, Khoury A, Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900
   PubMed Web of Science ®Google Scholar
• Walter K, Dilger C. Ibuprofen in human milk. Br J Clin Pharmacol 1997;44:211-2
   PubMed Web of Science ®Google Scholar
• Weibert RT, Townsend RJ, Kaiser DG, Lack of ibuprofen secretion into human milk. Clin Pharm 1982;1:457-8
   PubMedGoogle Scholar
• Rebordosa C, Kogevinas M, Bech BH, Use of acetaminophen during pregnancy and risk of adverse pregnancy outcomes. Int J Epidemiol 2009;38:706-14
   PubMed Web of Science ®Google Scholar
• Cleves MA, Savell VH Jr, Raj S, Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol 2004;70:107-13
   PubMed Web of Science ®Google Scholar
• McElhatton PR, Sullivan FM, Volans GN, Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Information Service of the National Poisons Information Service. Hum Exp Toxicol 1990;9:147-53
   PubMed Web of Science ®Google Scholar
• McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. Reprod Toxicol 1997;11:85-94
   PubMed Web of Science ®Google Scholar
• Thulstrup AM, Sorensen HT, Nielsen GL, Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Am J Perinatol 1999;16:321-6
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89
   PubMed Web of Science ®Google Scholar
• World Health Organization. Breastfeeding and Maternal Medication; 2002
   Google Scholar
• Banhidy F, Acs N, Puho E, Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol 2007;64:510-16
   PubMed Web of Science ®Google Scholar
• Soldin OP, Dahlin J, O'Mara DM. Triptans in pregnancy. Ther Drug Monit 2008;30:5-9
   PubMed Web of Science ®Google Scholar
• Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from The Norwegian Mother and Child Cohort Study. Headache 2010;50:563-75
   PubMed Web of Science ®Google Scholar
• Hogberg U, Wang M. SSRI during pregnancy and risk of fetal neurotoxicity. Follow precautions and look for other therapeutic alternatives. Lakartidningen 2005;102:113-15
   PubMedGoogle Scholar
• Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003;17:1-7
   PubMed Web of Science ®Google Scholar
• Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001;41:351-6
   PubMed Web of Science ®Google Scholar
• Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache 2009;49:1414-22
   PubMed Web of Science ®Google Scholar
• Fiore M, Shields KE, Santanello N, Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005;25:685-8
   PubMed Web of Science ®Google Scholar
• Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009;13:392-8
   PubMed Web of Science ®Google Scholar
• Matok I, Gorodischer R, Koren G, The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:2528-35
   PubMed Web of Science ®Google Scholar
• Berkovitch M, Elbirt D, Addis A, Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. N Engl J Med 2000;343:445-6
   PubMed Web of Science ®Google Scholar
• Berkovitch M, Mazzota P, Greenberg R, Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol 2002;19:311-16
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Nielsen GL, Christensen K, Birth outcome following maternal use of metoclopramide. The Euromap study group. Br J Clin Pharmacol 2000;49:264-8
   PubMed Web of Science ®Google Scholar
• Askenasy JJ, Streifler M, Felner S. The synaptic significance of metoclopramide induced dyskinetic-dystonic head and neck movements in pregnancy. J Neural Transm 1978;42:73-84
   PubMed Web of Science ®Google Scholar
• Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs 2008;23:292-9
   PubMedGoogle Scholar
• Dubow JS, Leikin J, Rezak M. Acute chorea associated with metoclopramide use. Am J Ther 2006;13:543-4
   PubMedGoogle Scholar
• van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 2006;64:160-2
   PubMed Web of Science ®Google Scholar
• Yis U, Ozdemir D, Duman M, Metoclopramide induced dystonia in children: two case reports. Eur J Emerg Med 2005;12:117-19
   PubMed Web of Science ®Google Scholar
• Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005;26:720-3
   PubMed Web of Science ®Google Scholar
• Djeddi D, Kongolo G, Lefaix C, Effect of domperidone on QT interval in neonates. J Pediatr 2008;153:663-6
   PubMed Web of Science ®Google Scholar
• Eghbali M, Wang Y, Toro L, Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 2006;16:285-91
   PubMed Web of Science ®Google Scholar
• Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183-92
   PubMed Web of Science ®Google Scholar
• Einarson A, Maltepe C, Navioz Y, The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76
   PubMed Web of Science ®Google Scholar
• Schroeder BM; AAFP, ACP-ASIM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician 2003;67:1392, 1395-7
   PubMed Web of Science ®Google Scholar
• Geraud G, Lanteri-Minet M, Lucas C, French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18
   PubMed Web of Science ®Google Scholar
• Magee LA, Schick B, Donnenfeld AE, The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174:823-8
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40
   PubMedGoogle Scholar
• Sorensen HT, Steffensen FH, Olesen C, Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol 1998;12:383-4
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Hannemann D, Meister R, The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 2008;26:24-30
   PubMed Web of Science ®Google Scholar
• Bott-Kanner G, Schweitzer A, Schoenfeld A, Treatment with propranolol and hydralazine throughout pregnancy in a hypertensive patient. A case report. Ir J Med Sci 1978;14:466-8
   Web of Science ®Google Scholar
• O'Connor PC, Jick H, Hunter JR, Propranolol and pregnancy outcome. Lancet 1981;2:1168
   PubMed Web of Science ®Google Scholar
• Campbell JW. A possible teratogenic effect of propranolol. N Engl J Med 1985;313:18
   Web of Science ®Google Scholar
• Redmond GP. Propranolol and fetal growth retardation. Semin Perinatol 1982;6:142-7
   PubMed Web of Science ®Google Scholar
• Lydakis C, Lip GY, Beevers M, Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999;12:541-7
   PubMed Web of Science ®Google Scholar
• Bayliss H, Churchill D, Beevers M, Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester? Hypertens Pregnancy 2002;21:161-74
   PubMed Web of Science ®Google Scholar
• Easterling TR, Carr DB, Brateng D, Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001;98:427-33
   PubMed Web of Science ®Google Scholar
• Tabacova S, Kimmel CA, Wall K, Atenolol developmental toxicity: animal-to-human comparisons. Birth Defects Res A Clin Mol Teratol 2003;67:181-92
   PubMed Web of Science ®Google Scholar
• Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther 2008;26:38-49
   PubMed Web of Science ®Google Scholar
• Lewis AJ, Galbally M, Opie G, Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust NZ J Psychiatry 2010;44:482-7
   PubMed Web of Science ®Google Scholar
• Santone G, Ricchi G, Rocchetti D, Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences. Epidemiol Psichiatr Soc 2009;18:240-7
   PubMed Web of Science ®Google Scholar
• Toh S, Mitchell AA, Louik C, Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009;29:555-60
   PubMed Web of Science ®Google Scholar
• Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21:221-2
   PubMed Web of Science ®Google Scholar
• Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;5:1-11
   Google Scholar
• Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-19
   PubMed Web of Science ®Google Scholar
• Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-20
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-18
   PubMed Web of Science ®Google Scholar
• Nordeng H, Lindemann R, Perminov KV, Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91
   PubMed Web of Science ®Google Scholar
• Moses-Kolko EL, Bogen D, Perel J, Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83
   PubMed Web of Science ®Google Scholar
• Sanz EJ, De-las-Cuevas C, Kiuru A, Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-7
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87
   PubMed Web of Science ®Google Scholar
• Levinson-Castiel R, Merlob P, Linder N, Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6
   PubMed Web of Science ®Google Scholar
• Cooper WO, Hernandez-Diaz S, Arbogast PG, Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51
   PubMed Web of Science ®Google Scholar
• Cooper WO. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors. J Cardiovasc Nurs 2008;23:20-4
   PubMed Web of Science ®Google Scholar
• From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy – United States, Canada, and Israel, 1987-1995. JAMA 1997;277:1193-4
   PubMed Web of Science ®Google Scholar
• Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 1992;80:429-32
   PubMed Web of Science ®Google Scholar
• Kreft-Jais C, Plouin PF, Tchobroutsky C, Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 1988;95:420-2
   PubMedGoogle Scholar
• Lip GY, Churchill D, Beevers M, Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997;350:1446-7
   PubMed Web of Science ®Google Scholar
• Steffensen FH, Nielsen GL, Sorensen HT, Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet 1998;351:596
   PubMed Web of Science ®Google Scholar
• Ray JG, Vermeulen MJ, Koren G. Taking ACE inhibitors during early pregnancy: is it safe? Can Fam Physician 2007;53:1439-40
   PubMed Web of Science ®Google Scholar
• Cunniff C, Jones KL, Phillipson J, Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 1990;162:187-9
   PubMed Web of Science ®Google Scholar
• Rosa FW, Bosco LA, Graham CF, Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989;74:371-4
   PubMed Web of Science ®Google Scholar
• Hanssens M, Keirse MJ, Vankelecom F, Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-35
   PubMed Web of Science ®Google Scholar
• Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynaecol 1998;38:306-11
   PubMed Web of Science ®Google Scholar
• Easterling TR, Carr DB, Davis C, Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 2000;96:956-61
   PubMed Web of Science ®Google Scholar
• Tabacova S, Little R, Tsong Y, Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003;12:633-46
   PubMed Web of Science ®Google Scholar
• Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23-8
   PubMed Web of Science ®Google Scholar
• Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-30
   PubMed Web of Science ®Google Scholar
• Martin U, Foreman MA, Travis JC, Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507-11
   PubMed Web of Science ®Google Scholar
• Riaz M, Porat R, Brodsky NL, The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol 1998;18:449-54
   PubMedGoogle Scholar
• Paulson GW. Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995;173:1734-41
   PubMed Web of Science ®Google Scholar
• Merlob P, Stahl B. Classification of drugs for teratogenic risk: an anachronistic way of counseling. Teratology 2002;66:61-2
   PubMedGoogle Scholar
• Clementi M, Cassina M, Di Gianantonio E. Medications in pregnancy and lactation. Obstet Gynecol 2009;114:166
   PubMed Web of Science ®Google Scholar